Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Narrative)

v3.22.1
Commitments and Contingencies (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Operating lease expense $ 54,960 $ 55,236
License Agreement $ 1,000,000  
Description of study drug and supplemental financial support The Company will provide study drug and supplemental financial support for the clinical trial  
Operating lease monthly payment $ 4,487  
Onxeo S.A    
Option and license agreement description the option agreement includes clinical, regulatory, developmental and sales milestones that could reach up to $108 million if the Company achieves all milestones, and escalating royalties on net sales from 5% to 10%  
Option and license agreement fee $ 1,000,000  
XOMA Ltd    
Option and license agreement description that could reach up to $14.925 million if the Company achieves all milestones  
GEIS    
Clinical-related expenses $ 300,000 $ 1,400,000